Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 235,595,689 papers from all fields of science
Search
Sign In
Create Free Account
tumor necrosis factor-alpha, CNGRC fusion protein, human
Known as:
CNGRC peptide-TNF alpha conjugate
, NGR-hTNF
, NGR-TNF, human
Expand
A cytokine-peptide conjugate composed of the cytokine tumor necrosis factor alpha (TNF-alpha) chemically linked to the peptide CNGRC. The peptide…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
NCIt Antineoplastic Agent Terminology
Broader (2)
Recombinant Fusion Proteins
Tumor Necrosis Factor-alpha
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Preparation and Tumor Targeting of NGR-SWCNTs-Paclitaxel
Zhang Yan-ya
2013
Corpus ID: 138151222
OBJECTIVE To investigate the best method for preparing NGR-SWCNTs-paclitaxel and observe its targeting efficency. METHODS SWCNTs…
Expand
2013
2013
Echtzeit-Bildgebung des Ansprechens muriner Tumore auf die anti-vaskuläre Therapie mittels tTF-NGR mithilfe Gadofosveset-verstärkter MRT
A. Höink
,
T. Persigehl
,
+4 authors
C. Schwöppe
2013
Corpus ID: 74835154
2011
2011
Cancer Therapy : Clinical Phase I Study of NGR-hTNF , a Selective Vascular Targeting Agent , in Combination with Cisplatin in Refractory Solid Tumors
V. Gregorc
,
F. Braud
,
+15 authors
C. Bordignon
2011
Corpus ID: 37683203
Purpose: NGR-hTNF exploits the tumor-homing peptide asparagine-glycine-arginine (NGR) for selectively targeting TNF-a to an…
Expand
2011
2011
Background and Methods Background and methods Results Randomized phase II trial of NGR-hTNF and chemotherapy in chemo-naïve patients with non-small cell lung cancer (NSCLC): preliminary results
V. Gregorc
,
N. Zilembo
,
+7 authors
C. Bordignon
2011
Corpus ID: 78533077
2010
2010
Molecule of the month. NGR-hTNF.
Drug News and Perspectives
2010
Corpus ID: 34299532
2009
2009
Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM).
V. Gregorc
,
G. Ceresoli
,
+7 authors
Claudio Bordignon
Journal of Clinical Oncology
2009
Corpus ID: 28588133
7582 Background: NGR-hTNF is a VTA exploiting a tumor-homing peptide (NGR) that selectively binds to an aminopeptidase N (CD13…
Expand
2008
2008
A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients (pts) with solid tumors
F. Braud
,
V. Gregorc
,
+7 authors
C. Bordignon
2008
Corpus ID: 74235371
14647 Background: NGR-hTNF is a VTA exploiting a tumor-homing peptide (NGR) that selectively binds to aminopeptidase N/CD13…
Expand
2008
2008
Safety and antitumour activity of NGR-hTNF, a selective vascular targeting agent (VTA), administered at low dose in pre-treated patients with hepatocellular carcinoma (HCC): preliminary results of a…
G. Citterio
,
A. Santoro
,
+6 authors
C. Bordignon
2008
Corpus ID: 74552104
Background: NGR-hTNF is a VTA exploiting a tumour homing peptide (NGR) selectively binding angiogenic vessels in solid tumours…
Expand
2008
2008
Serum omentin level and related factors in obese and type 2 diabetic patients
R. Cai
,
Li Wei
,
Hai–ya Wu
,
Y. Bao
,
W. Jia
,
K. Xiang
2008
Corpus ID: 221011624
Objective To assay the serum omentin level in obese and newly diagnosed type 2 diabetes mellitus (T2DM) patients and investigate…
Expand
2007
2007
Liminality and loss: The material culture of St Serf ‘s priory, Loch Leven, Kinross-Shire, Scotland
M. Hall
2007
Corpus ID: 162150949
St Serf 's Priory also known as the Priory of Lochleven, survives as a ruin on the largest island in Lochleven, St Serf 's Island…
Expand